Cancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Cancer Immunol Immunother. 2022 Apr;71(4):989-998. doi: 10.1007/s00262-021-03047-7. Epub 2021 Sep 27.
Despite the conventional view that a truly random V(D)J recombination process should generate a highly diverse immune repertoire, emerging reports suggest that there is a certain bias toward the generation of shared/public immune receptor chains. These studies were performed in viral diseases where public T cell receptors (TCR) appear to confer better protective responses. Selective pressures generating common TCR clonotypes are currently not well understood, but it is believed that they confer a growth advantage. As very little is known about public TCR clonotypes in cancer, here we set out to determine the extent of shared TCR clonotypes in the intra-tumor microenvironments of virus- and non-virus-driven head and neck cancers using TCR sequencing. We report that tumor-infiltrating T cell clonotypes were indeed shared across individuals with the same cancer type, where the majority of shared sequences were specific to the cancer type (i.e., viral versus non-viral). These shared clonotypes were not particularly enriched in EBV-associated nasopharynx cancer but, in both cancers, exhibited distinct characteristics, namely shorter CDR3 lengths, restricted V- and J-gene usages, and also demonstrated convergent V(D)J recombination. Many of these shared TCRs were expressed in patients with a shared HLA background. Pattern recognition of CDR3 amino acid sequences revealed strong convergence to specific pattern motifs, and these motifs were uniquely found to each cancer type. This suggests that they may be enriched for specificity to common antigens found in the tumor microenvironment of different cancers. The identification of shared TCRs in infiltrating tumor T cells not only adds to our understanding of the tumor-adaptive immune recognition but could also serve as disease-specific biomarkers and guide the development of future immunotherapies.
尽管传统观点认为,真正随机的 V(D)J 重组过程应该产生高度多样化的免疫受体库,但新出现的报告表明,存在着产生共享/公共免疫受体链的某种偏向。这些研究是在病毒性疾病中进行的,其中公共 T 细胞受体(TCR)似乎能提供更好的保护反应。产生公共 TCR 克隆型的选择压力目前还不太清楚,但人们相信它们赋予了生长优势。由于人们对癌症中的公共 TCR 克隆型知之甚少,在这里,我们着手使用 TCR 测序来确定病毒和非病毒驱动的头颈部癌症肿瘤内微环境中共享 TCR 克隆型的程度。我们报告说,肿瘤浸润性 T 细胞克隆型确实在具有相同癌症类型的个体之间共享,其中大多数共享序列是特定于癌症类型的(即病毒与非病毒)。这些共享克隆型在 EBV 相关的鼻咽癌中并没有特别富集,但在这两种癌症中,它们都表现出独特的特征,即 CDR3 长度较短、V 和 J 基因使用受限,并且还表现出趋同的 V(D)J 重组。这些共享 TCR 中的许多在具有共享 HLA 背景的患者中表达。对 CDR3 氨基酸序列的模式识别显示出对特定模式基序的强烈趋同,并且这些基序在每种癌症类型中都是独特的。这表明它们可能富含在不同癌症的肿瘤微环境中发现的共同抗原的特异性。在浸润性肿瘤 T 细胞中鉴定出共享 TCR,不仅增加了我们对肿瘤适应性免疫识别的理解,而且还可以作为疾病特异性生物标志物,并指导未来免疫疗法的发展。